XML 99 R86.htm IDEA: XBRL DOCUMENT v3.23.1
Further Detail of Profit or Loss (Details) - Schedule of further detail of profit or loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
A. Research and development expenses, net      
Payroll $ 35,638 $ 14,604 $ 4,849
Share-based payment expenses 17,424 14,238 1,682
Materials 6,881 2,764 940
Subcontractors 10,344 2,864 258
Patent registration 506 441 160
Depreciation 3,038 5,697 1,588
Rental fees and maintenance 642 559 173
Other 1,290 637 249
Research and development expenses, gross 75,763 41,804 9,899
Less – government grants   (118) (21)
Research and development expenses, net 75,763 41,686 9,878
B. Sales and marketing expenses      
Payroll 20,057 8,283 3,336
Share-based payment expenses 8,616 8,569 1,990
Marketing, advertising and commissions 5,057 4,053 577
Rental fees and maintenance 392 365 201
Travel abroad 2,567 749 235
Depreciation 1,502 318 223
Other 642 376 35
Sales and marketing expenses 38,833 22,713 6,597
C. General and administrative expenses      
Payroll 9,321 2,880 1,377
Share-based payment expenses 4,940 6,974 16,837
Fees 17 33 22
Professional services 9,701 6,993 1,064
Office expenses 2,704 1,065 386
Travel abroad 743 461 44
Depreciation 563 210 76
Rental fees and maintenance 286 97 46
Other 2,182 931 435
General and administrative expenses 30,457 19,644 20,287
D. Finance income      
Revaluation of liability in respect of government grants   25 75
Exchange rate differences   3,444 123
Revaluation of liabilities [1] 4,516 10,608
Bank interest 18,449 3,832 248
Finance income 22,965 17,909 446
Finance expense      
Exchange rate differences 16,135    
Bank and institutions fees 148 70 28
Finance expense in respect of lease liability 180 237 390
Revaluation of financial assets at FV through profit and loss [2] 62,791
Revaluation of financial liabilities [1] 12,825
Revaluation of liability in respect of government grants 217 121
Finance expense $ 79,471 $ 428 $ 13,243
[1] See Note 20 regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.
[2] See note 20(F) regarding investment in securities measured at fair value through profit and loss.